MAGEA1 peptide-HLA-A*02:01 complex

The **MAGEA1 peptide-HLA-A*02:01 complex** is a molecular bridge for immune recognition in cancer immunotherapy, consisting of a peptide epitope from the MAGEA1 protein bound and presented by the HLA-A*02:01 major histocompatibility class I molecule. This complex allows cytotoxic CD8+ T cells, via their T cell receptors, to selectively recognize and eradicate tumor cells expressing MAGEA1. MAGEA1 is a cancer-testis antigen, typically restricted to cancer and testis tissue, making it an attractive and relatively specific target for adoptive cell transfer (ACT) therapies and cancer vaccines. Therapeutic intervention relies on engineering TCRs to specifically recognize the MAGEA1 peptide-HLA-A*02:01 complex on cancer cells, with aim to trigger tumor cell lysis. While promising, the strategy requires careful safety evaluation due to off-target risks linked to peptide similarities with proteins in normal tissues[2][3][4].

Other names

MAGE-A1 peptide-HLA-A2 complexMAGEA1/HLA-A*02:01MAGEA1 epitope-HLA-A*02:01

Recognition by engineered TCRs or vaccine-elicited cytotoxic T cells leads to immune-mediated killing of cancer cells presenting MAGEA1 in the context of HLA-A*02:01[2][4].